Synopsis

Spinal cord stimulation (SCS) is primarily used to treat persistent back and leg pain following spine surgery, but minimal evidence existed to show efficacy in patients who were surgery naïve. This randomized controlled trial was designed to demonstrate the clinical efficacy of 10kHz SCS in chronic back pain patients who were surgery naïve and not acceptable candidates for surgery. Recently published 12-month results showed profound improvements in pain relief, function, and quality of life with 10kHz SCS over conventional medical management for non-surgical refractory back pain (NSRBP) patients. We now report 18-month results demonstrating the durability of these therapeutic outcomes.

Disclosures

• Taissa Cherry, MD has contracted research with Nevro Corp, with all funds going to her institution
• Jessica Jameson, MD receives consulting and speaking fees from Nevro, Boston Scientific
• Naresh P. Patel, MD has contracted research with Nevro Corp, with all funds going to his institution
  
• Curtis Johnson, MD has contracted research with Nevro Corp
• Daniel Kloster, MD has contracted research with Nevro Corp
• Aaron K. Calodney, MD AC receives consulting fees from Nevro Corp.
• Rose Province-Azalde, MS Employee of Nevro Corp.
• Leonardo Kapural, MD, PhD on scientific advisory board for Abbott, Nevro, Saluda, SPR therapeutics, Neuros, Halyard. Is a consultant: Gimer Medical, Best Doctors, Solis Medical, Nalu Medical, Biotronik, Nevro, and has research contracts with Stimwave, Nevro, Neuros, Halyard, SPR therapeutics, Boston Scientific, Medtronic, Saluda.